Fluoroquinolone use and Clostridium difficile-associated diarrhea

Emerging Infectious Diseases

Volumn 9, Issue 6, 2003, Pages 730-733

  McCusker, Margaret E ^a   Harris, Anthony D ^b   Perencevich, Eli ^b   Roghmann, Mary Claire ^a,b  

^a UNIVERSITY OF MARYLAND   (United States)

^b Veteran Affairs Maryland Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; GATIFLOXACIN; LEVOFLOXACIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; INFECTION RATE; MALE; MULTIVARIATE ANALYSIS; NOSOCOMIAL DIARRHEA; RISK FACTOR;

EID: 0038387431     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0906.020385     Document Type: Article

References (17)

1. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027-36.
2. Gorbach SL. Antibiotics and Clostridium difficile. N Engl J Med 1999;341:1690-1.
3. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
4. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-9.
5. Kyne L, Hamel MB, Polavarm R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 2002;34:346-53.
6. Bates CJ, Wilcox MH, Spencer RC, Harris DM. Ciprofloxacin and Clostridium difficile infection. Lancet 1990;336:1193.
7. Cain DB, O'Connor ME. Pseudomembranous colitis associated with ciprofloxacin. Lancet 1990;336:946.
8. Low N, Harries A. Ciprofloxacin and pseudomembranous colitis. Lancet 1990;336:1509-10.
9. McFarland LV, Bauwens JE, Melcher SA, Surawicz CM, Greenberg RN, Elmer GW. Ciprofloxacin-associated Clostridium difficile disease. Lancet 1995;346:977.
10. Bauwens JE, McFarland LV, Melcher SA. Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997;31:1090.
11. Ozawa TT, Valadez T. Clostridium difficile infection associated with levofloxacin treatment. Tenn Med 2002;95:113-5.
12. Golledge CL, Carson CF, O'Neill GL, Bowman RA, Riley TV. Ciprofloxacin and Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 1992;30:141-7.
13. Yip C, Loeb M, Salama S, Moss L, Olde J. Quinolone use as a risk factor for nosocomial Clostridium difficile associated diarrhea. Infect Control Hosp Epidemiol 2001;22:572-5.
14. Alonso R, Pelaez T, Gonzalez-Abad MJ, Alcala L, Munoz P, Rodriguez-Creixems M, et al. In vitro activity of new quinolones against Clostridium difficile. J Antimicrob Chemother 2001;47:195-7.
15. Lew MA, Kehoe K, Ritz J, Antman KH, Nadler L, Kalish LA, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995;13:239-50.
16. Katz DA, Lynch ME, Littenberg B. Clinical prediction rules to optimize cytotoxin testing for Clostridium difficile in hospitalized patients with diarrhea. Am J Med 1996;100:487-95.
17. Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM. Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 1998;128:989-95.